These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37873426)

  • 21. Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
    Wang S; Niroula S; Hoffman A; Khorrami M; Khorrami M; Yuan F; Gasser GN; Choi S; Liu B; Li J; Metersky ML; Vincent M; Crum CP; Boucher RC; Karmouty-Quintana H; Huang HJ; Sheshadri A; Dickey BF; Parekh KR; Engelhardt JF; McKeon FD; Xian W
    Am J Respir Crit Care Med; 2023 Nov; 208(9):930-943. PubMed ID: 37695863
    [No Abstract]   [Full Text] [Related]  

  • 22. Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses.
    Sosnay PR; Salinas DB; White TB; Ren CL; Farrell PM; Raraigh KS; Girodon E; Castellani C
    J Pediatr; 2017 Feb; 181S():S27-S32.e1. PubMed ID: 28129809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cystic fibrosis.
    Fajac I; Burgel PR
    Presse Med; 2023 Sep; 52(3):104169. PubMed ID: 37516246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional Consequences of CFTR Interactions in Cystic Fibrosis.
    Ramananda Y; Naren AP; Arora K
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor.
    Li H; Rodrat M; Al-Salmani MK; Veselu DF; Han ST; Raraigh KS; Cutting GR; Sheppard DN
    J Physiol; 2024 Jan; 602(2):333-354. PubMed ID: 38186087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment.
    Raraigh KS; Aksit MA; Hetrick K; Pace RG; Ling H; O'Neal W; Blue E; Zhou YH; Bamshad MJ; Blackman SM; Gibson RL; Knowles MR; Cutting GR
    J Cyst Fibros; 2022 May; 21(3):463-470. PubMed ID: 34782259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How the sweat gland reveals levels of CFTR activity.
    Wine JJ
    J Cyst Fibros; 2022 May; 21(3):396-406. PubMed ID: 35184981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive
    Minso R; Schulz A; Dopfer C; Alfeis N; Barneveld AV; Makartian-Gyulumyan L; Hansen G; Junge S; Müller C; Ringshausen FCC; Sauer-Heilborn A; Stanke F; Stolpe C; Tamm S; Welte T; Dittrich AM; Tümmler B
    BMJ Open Respir Res; 2020 Oct; 7(1):. PubMed ID: 33020115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-terminal CFTR missense variants severely affect the behavior of the CFTR chloride channel.
    Gené GG; Llobet A; Larriba S; de Semir D; Martínez I; Escalada A; Solsona C; Casals T; Aran JM
    Hum Mutat; 2008 May; 29(5):738-49. PubMed ID: 18306312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis.
    Mickle JE; Macek M; Fulmer-Smentek SB; Egan MM; Schwiebert E; Guggino W; Moss R; Cutting GR
    Hum Mol Genet; 1998 Apr; 7(4):729-35. PubMed ID: 9499426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cystic fibrosis: molecular update and clinical implications].
    Orozco L; Chávez M; Saldaña Y; Velázquez R; Carnevale A; González-del Angel A; Jiménez S
    Rev Invest Clin; 2006; 58(2):139-52. PubMed ID: 16827266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refining the continuum of CFTR-associated disorders in the era of newborn screening.
    Levy H; Nugent M; Schneck K; Stachiw-Hietpas D; Laxova A; Lakser O; Rock M; Dahmer MK; Biller J; Nasr SZ; Baker M; McColley SA; Simpson P; Farrell PM
    Clin Genet; 2016 May; 89(5):539-49. PubMed ID: 26671754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators.
    Han ST; Rab A; Pellicore MJ; Davis EF; McCague AF; Evans TA; Joynt AT; Lu Z; Cai Z; Raraigh KS; Hong JS; Sheppard DN; Sorscher EJ; Cutting GR
    JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine.
    McDonald EF; Meiler J; Plate L
    ACS Chem Biol; 2023 Oct; 18(10):2128-2143. PubMed ID: 37730207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies.
    Anwar S; Peng JL; Zahid KR; Zhou YM; Ali Q; Qiu CR
    Adv Respir Med; 2024 Jul; 92(4):263-277. PubMed ID: 39051188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next-Generation Sequencing for Screening Analysis of Cystic Fibrosis: Spectrum and Novel Variants in a South-Central Italian Cohort.
    De Paolis E; Tilocca B; Lombardi C; De Bonis M; Concolino P; Onori ME; Ricciardi Tenore C; Perrucci A; Roncada P; Capoluongo E; Urbani A; Minucci A; Santonocito C
    Genes (Basel); 2023 Aug; 14(8):. PubMed ID: 37628659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlating genotype with phenotype using CFTR-mediated whole-cell Cl
    Noel S; Servel N; Hatton A; Golec A; Rodrat M; Ng DRS; Li H; Pranke I; Hinzpeter A; Edelman A; Sheppard DN; Sermet-Gaudelus I
    J Physiol; 2022 Mar; 600(6):1515-1531. PubMed ID: 34761808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Multifaceted Roles of MicroRNAs in Cystic Fibrosis.
    De Palma FDE; Raia V; Kroemer G; Maiuri MC
    Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33348555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.